Literature DB >> 20589451

Levodopa-responsive parkinsonism after aneurysmal subarachnoid hemorrhage.

Jeremy D Fields1, Justin S Cetas.   

Abstract

BACKGROUND: Levodopa-responsive Parkinsonism is a rare complication of subarachnoid hemorrhage and no cases have been reported to occur in the absence of hydrocephalus.
METHODS: Case report.
RESULTS: We describe a 42-year-old woman who developed progressive severe Parkinsonism in the second week after aneurysmal subarachnoid hemorrhage. No hydrocephalus was present. Neuroimaging revealed striking abnormalities of the midbrain in the region of the substantia nigra. She was ultimately treated with high dose levodopa/carbidopa with a dramatic response.
CONCLUSIONS: This case suggests that Parkinsonism may occur as a delayed complication of subarachnoid hemorrhage, and that in these patients, a trial of levodopa-carbidopa may be warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20589451     DOI: 10.1007/s12028-010-9398-2

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  5 in total

1.  Akinetic mutism from frontal lobe damage responding to levodopa.

Authors:  O Combarros; J Infante; J Berciano
Journal:  J Neurol       Date:  2000-07       Impact factor: 4.849

2.  Drug-induced parkinsonism.

Authors:  Frandy Susatia; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

3.  Intracranial hypotension with parkinsonism, ataxia, and bulbar weakness.

Authors:  A S Pakiam; C Lee; A E Lang
Journal:  Arch Neurol       Date:  1999-07

Review 4.  Subarachnoid haemorrhage and akinetic mutism.

Authors:  K A Choudhari
Journal:  Br J Neurosurg       Date:  2004-06       Impact factor: 1.596

Review 5.  Lyme-associated parkinsonism: a neuropathologic case study and review of the literature.

Authors:  David S Cassarino; Martha M Quezado; Nitya R Ghatak; Paul H Duray
Journal:  Arch Pathol Lab Med       Date:  2003-09       Impact factor: 5.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.